Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* History of chronic HCV infection (≥ 6 months)~* HCV genotype 1, 2, 3, 4, 5, 6, or indeterminate~* Liver transplant ≥ 3 months prior to screening~* Male and nonpregnant/ non-lactating female individuals without cirrhosis or with compensated cirrhosis~Key Exclusion Criteria:~* History of clinically significant illness or any other medical disorder that may interfere with individual's treatment, assessment or compliance with the protocol,~* Co-infection with HIV or hepatitis B virus~* Known hypersensitivity to study medication,~* Use of any prohibited concomitant medications as within with window before the Day 1 visit.~* De novo or recurrent hepatocellular carcinoma posttransplant~NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL (Type: EXPERIMENTAL): SOF/VEL FDC for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).